Itralent SB 65 Capsule contains Itraconazole 65 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itralent SB 65 is effective against a wide range of pathogenic fungi including dermatophytes, yeasts such as Candida species, and molds including Aspergillus species. It is commonly prescribed for conditions such as onychomycosis, blastomycosis, histoplasmosis, and other systemic mycoses. The capsule formulation allows for convenient oral administration, with absorption enhanced when taken with food. Dosage and duration of therapy should be tailored according to the type and severity of infection, as well as patient-specific factors. Caution is advised in patients with hepatic impairment, and potential drug interactions must be considered due to itraconazole’s effect on cytochrome P450 enzymes. Monitoring liver function tests during prolonged therapy is recommended to mitigate adverse effects. Itralent SB 65 provides an effective therapeutic option for managing challenging fungal infections under medical supervision.